Characterization of Micro and Nanoparticles for Biomedical Applications is a helpful guide for industry researchers, academicians, regulatory experts and material scientists working in the field of pharmaceuticals, cosmeceuticals, nutraceuticals, agriculture, food, fragrance, and in the chemical industries. It aims to provide a one-stop resources on all the analytical techniques used in the field of micro and nanoparticles evaluation and characterization. The book's chapters bring together knowledge on current analytical methodologies, limitations and advances in the in vitro analysis field. Users from the equipment industry will benefit from its innovations by understanding the needs of researchers and the challenges of current techniques. With the expectation of "high-quality data" essentially dependent on the analytical methodology applied for characterization, this is integral to success. For routine products like tablets, capsules, and solutions, the regulatory guidelines, product-specific monographs, and pharmacopoeial annexures are set and "standard of operation." However, for nano-micro pharmaceuticals, regulatory guidelines are still evolving.
Table of Contents
1. Particle size analysis2. Zeta potential and surface characterization (eg, porosity, BET, hydrophilicity, etc.)
3. Microscopic analysis (AFM, SEM, TEM) etc.
4. XRD-EDS- crystallinity, compatibility
5. Isotonicity, osmolarity, osmolality, plasma/blood compatibility
6. In vitro release testing (including Franz diffusion cells)
7. Nanoparticle tracking analysis
8. Chemical analysis
9. Thermal analysis- DSC, TGA etc.
10. Chromatographic analyses (all)
11. Drug loading, entrapment assays of nano and micro particles: current practices
12. Nanoparticle dissolution
13. Sterility testing nanoparticles
14. Lyophilization characterization
Authors
Ranjita Shegokar Postdoctoral Researcher, Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Free University of Berlin, Germany.Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Currently, she serves as Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited many trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received many prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems. (www.ranjitas.com)
Eliana B. Souto Professor, Department of Pharmaceutical Technology of the Faculty of Pharmacy, University of Porto, Portugal. Eliana B. Souto is Habil. Professor from the Department of Pharmaceutical Technology of the Faculty of Pharmacy of University of Porto. Prof. Souto graduated in Pharmaceutical Sciences from University of Coimbra (2000), is holder of a master's in science degree in Pharmaceutical Technology from University of Porto (2002), and PhD in Pharmaceutical Nanotechnology and Biopharmaceutics from the Institut fuer Pharmazie der Freie Universitaet Berlin, Germany (2005). Her research lines include the design, development, and characterization of new drug delivery systems to overcome biological barriers. Prof. Souto serves as Associate Editor, member of the Editorial Board, and Reviewer of several international scientific journals and has published more than 500 works (original and review papers, books and book chapters) in the field of nanosciences and nanomedicine. Prof. Souto also acts as independent expert for several national, European and international funding agencies, and as consultant for pharmaceutical industry.
